Compare · EDIT vs GILD
EDIT vs GILD
Side-by-side comparison of Editas Medicine Inc. (EDIT) and Gilead Sciences Inc. (GILD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both EDIT and GILD operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- GILD is the larger of the two at $161.45B, about 521.9x EDIT ($309.4M).
- Over the past year, EDIT is up 15.5% and GILD is up 19.2% - GILD leads by 3.8 points.
- Both names hit the wire about 5 times in the past 4 weeks.
- Both have 25 recent analyst ratings on file.
- Company
- Editas Medicine Inc.
- Gilead Sciences Inc.
- Price
- $3.17+0.16%
- $130.00-1.07%
- Market cap
- $309.4M
- $161.45B
- 1M return
- +30.45%
- +3.32%
- 1Y return
- +15.48%
- +19.24%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2016
- 1992
- News (4w)
- 5
- 5
- Recent ratings
- 25
- 25
Editas Medicine Inc.
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary genome editing platform based on CRISPR technology to target genetically addressable diseases and therapeutic areas. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis type 10, a genetic form of vision loss that leads to blindness in childhood. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa 4, a progressive form of retinal degeneration; and EDIT-301 to treat sickle cell disease and beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumors; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer, as well as has a early discovery program to develop a therapy to treat a neurological disease. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and research collaboration with Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease, as well as research collaboration with AskBio and collaboration with m BlueRock Therapeutics LP. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
Gilead Sciences Inc.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
Latest EDIT
- SEC Form 4 filed by Director Connaughton Bernadette
- SEC Form 4 filed by Director Hopfield Jessica
- SEC Form 4 filed by Director Hirsch Andrew
- SEC Form 4 filed by Director Scadden David
- SEC Form 4 filed by Director Levy Elliott M.
- Editas Medicine Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- SVP, Chief Financial Officer Parison Amy sold $1,253 worth of shares (464 units at $2.70), decreasing direct ownership by 3% to 14,970 units (SEC Form 4) to satisfy tax liability
- CEO O'Neill Gilmore Neil sold $41,543 worth of shares (15,380 units at $2.70), decreasing direct ownership by 6% to 248,313 units (SEC Form 4) (for withholding tax)
- EVP, CHIEF SCIENTIFIC OFFICER Burkly Linda sold $1,975 worth of shares (731 units at $2.70), decreasing direct ownership by 1% to 67,297 units (SEC Form 4) to satisfy withholding tax
- SEC Form SCHEDULE 13G filed by Editas Medicine Inc.
Latest GILD
- Gilead Sciences upgraded by HSBC Securities with a new price target
- Chairman & CEO O'Day Daniel Patrick sold $1,894,400 worth of shares (15,000 units at $126.29) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 607,133 units (SEC Form 4)
- U.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast Cancer
- Next-Generation DNA Repair Inhibitors Could Capture Billions in Emerging Market
- European Commission Approves Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-(l)1 Inhibitors
- Chief Comm & Corp Aff Officer Mercier Johanna sold $371,762 worth of shares (3,000 units at $123.92) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 124,234 units (SEC Form 4)
- Chief Financial Officer Dickinson Andrew D sold $376,200 worth of shares (3,000 units at $125.40) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 171,646 units (SEC Form 4)
- U.S. FDA Accepts Gilead's Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention
- Gilead Mobilizes Rapid Donation of Remdesivir to Support Ebola Response, Building on Decade-Long Commitment to Outbreak Relief
- Chief Medical Officer Berger Dietmar covered exercise/tax liability with 263 shares and converted options into 533 shares, increasing direct ownership by 1% to 19,252 units (SEC Form 4)